Overview

This trial is active, not recruiting.

Conditions acute coronary syndrome, myocardial infarction
Sponsor Uppsala University
Collaborator AstraZeneca
Start date January 2006
Trial size 78000 participants
Trial identifier NCT01623700, U-11-001

Summary

This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are merged into The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART).

The aim of this study is to investigate the impact of different antithrombotic treatment options (treatment duration, type of treatment and combination of treatments) in Acute Coronary Syndrome (ACS) patients on outcomes such as recurrent ischemic events and mortality.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective
Arm

Primary Outcomes

Measure
number of patients with adverse events in patient groups with different antithrombotic treatment strategies
time frame: up to 5 years and 6 months

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patient with an event of ACS under the study period - Patient found in the National Registry of Drug Prescriptions and treated or not treated with antithrombotic drug/s (acetylsalicylic acid and/or either clopidogrel/ticlopidine/prasugrel and/or warfarin) Exclusion Criteria: - Patients will not be excluded from the database if they fulfill inclusion criteria.

Additional Information

Official title A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
Principal investigator Stefan James, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in June 2012.
Information provided to ClinicalTrials.gov by Uppsala University.